Table 5 Baseline characteristics among patients who prematurely discontinued and patients who completed the study
Characteristic | Patients with premature discontinuation (N = 34) | Patients completing the study (N = 109) |
|---|---|---|
Age, years | ||
Mean (SD) | 38.8 (10.7) | 41.9 (11.6) |
Median (range) | 36 (21–64) | 42 (21–79) |
Gender, n (%) | ||
Women | 26 (76.5) | 73 (67.0) |
Men | 8 (22.5) | 36 (33.0) |
Duration of disease, months | N = 26 | N = 76 |
Mean (SD) | 44.8 (60.7) | 61.6 (76.5) |
Median (range) | 24.8 (0.0–274.9) | 33.6 (0.0–372.6) |
EDSS, median (range)) | N = 28 | N = 96 |
2.3 (0–6.0); | 2.0 (0–6.5); | |
Previous treatment, n (%) | ||
Betaferon® | 30 (88.2) | 76 (69.7) |
Other treatment | 2 (5.9) | 4 (3.7) |
No previous treatment | 2 (5.9) | 29 (26.6) |
Previous usage of auto-injector for Betaferon® treatment among patients who received Betaferon® previously, n (%) | N = 30 | N = 76 |
Any | 23 (76.7) | 61 (80.3) |
BETACOMFORT® | 15 (60.0) | 36 (59.0) |
BETAJECT Comfort® | 8 (32.0) | 12 (19.7) |
BETAJECT lite® | - | 3 (4.9) |
Other | - | 10 (16.4) |
BETAPLUS® participation, n (% of FAS) | 26 (76.5) | 61 (56.0) |